3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
118
Lung Neoplasms
9
Neoplasms
8
Triple Negative Breast Neoplasms
7
Ovarian Neoplasms
7
Neoplastic Cells, Circulating
6
Neoplasm Metastasis
5
Prostatic Neoplasms
4
Recurrence
3
Pancreatic Neoplasms
3
Hodgkin Disease
3
Hereditary Breast and Ovarian Cancer Syndrome
3
Head and Neck Neoplasms
3
Gastrointestinal Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Obesity
2
Melanoma
2
Lymphoma
2
Liver Neoplasms
2
Leukemia
2
Genetic Diseases, Inborn
2
Fibrosis
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Breast Diseases
2
Vulvar Neoplasms
1
Interventions
Trastuzumab
33
pertuzumab
18
Docetaxel
16
pyrotinib
15
Paclitaxel
7
Capecitabine
6
tucatinib
5
Carboplatin
5
Ado-Trastuzumab Emtansine
4
trastuzumab deruxtecan
3
neratinib
3
atezolizumab
2
Protons
2
Neoadjuvant Therapy
2
Fulvestrant
2
pegfilgrastim
1
palbociclib
1
margetuximab
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
envafolimab
1
dalpiciclib
1
Taxoids
1
Metformin
1
Leuprolide
1
Letrozole
1
Isovaleryl-CoA Dehydrogenase
1
Injections
1
Hospital Information Systems
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-positive Breast Cancer
×
Blood Specimen Collection
×
Breast
×
Clear all
NCT04638725
2026-06-04
SIGHER
Centre Paul Strauss
Recruiting
9,000 enrolled